|
Kidney Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
APOL1 is expressed in renal cells, however, the pathogenic events that lead to renal cell damage and kidney disease are not fully understood.
|
31661509 |
2019 |
|
Kidney Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
APOL1 is expressed in glomerular podocytes and does not vary with underlying kidney disease diagnoses or APOL1 genotypes, suggesting that the kidney disease-associated variants dysregulate its function rather than its localization or abundance.
|
28724794 |
2017 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
No evidence for association between APOL1 kidney disease risk alleles and Human African Trypanosomiasis in two Ugandan populations.
|
29470556 |
2018 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
These include: (1) the intra-renal renin-angiotensin system (RAS), one based on molecular variations in angiotensinogen; (2) the Na, K, 2Cl cotransporter (NKCC2) and its regulators in the thick ascending limb, which are associated with a variety of phenotypes consistent with a more active cotransporter in blacks; and (3) the genes for MYH9 and APOL 1, which have been associated with kidney disease in blacks.
|
23397215 |
2013 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we discuss the possibility that abnormal efflux of cellular potassium or other cations may be relevant to the pathogenesis of APOL1 nephropathy.
|
29110762 |
2017 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
MYH9 and APOL1 are both associated with sickle cell disease nephropathy.
|
21910715 |
2011 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Gene-gene interactions in APOL1-associated nephropathy.
|
24157943 |
2014 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
This article reviews the current status of APOL1-associated nephropathy and discusses research questions under active investigation in the search for a cure for these severe and often progressive kidney diseases.
|
24119848 |
2013 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Since HIVAN has the strongest association with APOL1 genotype of any of the APOL1-associated nephropathies, studies to determine the mechanisms by which HIV and APOL1 risk variants together promote kidney injury hold great promise to improve our understanding of the pathogenesis of APOL1-mediated kidney diseases.
|
29930940 |
2018 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Transcript analysis of mouse kidney disease models, including folic-acid (FA)-induced nephropathy, unilateral ureteral obstruction (UUO), or apolipoprotein L1 (APOL1)-associated kidney disease, indicated that Jag1 and Notch2 levels were higher in all analyzed kidney fibrosis models.
|
30226866 |
2018 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Our study not only reveals the contribution of each domain of the APOL1 protein to cell injury, but also highlights some potential suggested targets for drug design to prevent or treat APOL1-associated nephropathy.
|
26091559 |
2015 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Detection of APOL1 associations with kidney diseases and delineation of injury pathways brings hope for effective treatment for these kidney diseases.
|
30343724 |
2018 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Heterogeneity in study population and study design has led to differing reports on the role of APOL1 nephropathy risk variants in CVD.
|
31082862 |
2019 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The linkage peak on chromosome 22q overlaps the MYH9/APOL1 gene region, previously implicated in AA diabetic and nondiabetic nephropathies.
|
21454968 |
2011 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, although variants with small individual effects cannot be ruled out and are likely to exist, our results suggest that APOL1-environment interactions may be of greater clinical importance in triggering nephropathy in African Americans than APOL1 interactions with other single nucleotide polymorphisms.
|
29885931 |
2018 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
APOL1-associated nephropathy typically occurs in association with certain environmental factors or systemic diseases.
|
31601430 |
2020 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Further studies to identify additional second hits are necessary to better understand the pathologic mechanisms of donor APOL1-associated kidney disease in the recipient.
|
30054024 |
2019 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
APOL1 nephropathy risk alleles.
|
31563468 |
2020 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Therapeutic strategies for APOL1-associated nephropathies will require the prevention and treatment of these 'second hits' and the development of drugs to protect the APOL1 downstream renal injury pathways.
|
25561578 |
2016 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
An evolving understanding of the pathogenesis of APOL1-mediated kidney damage may aid in personalized medicine approaches to APOL1 attributable kidney disease.
|
29406442 |
2018 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The APOL1-associated spectrum of nondiabetic nephropathy also includes proteinuric kidney diseases, idiopathic focal segmental glomerulosclerosis, collapsing glomerulopathy, severe lupus nephritis, and sickle cell nephropathy.
|
31023447 |
2019 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Combined Effects of GSTM1 Null Allele and APOL1 Renal Risk Alleles in CKD Progression in the African American Study of Kidney Disease and Hypertension Trial.
|
26940095 |
2016 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Uncontrolled or poorly controlled human immunodeficiency virus (HIV) infection is the most potent susceptibility factor for APOL1 nephropathy that has been identified to date.
|
29110758 |
2017 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Second hits appear necessary for the initiation of APOL1-associated nephropathy.
|
22695330 |
2012 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, IONIS-APOL1Rx may be an effective therapeutic for APOL1 nephropathies and warrants further development.
|
31217349 |
2019 |